Therapy of atopic eczema with calcineurin inhibitors;Therapie des atopischen ekzems mit calcineurin-inhibitoren

JDDG - Journal of the German Society of Dermatology

Volumn 3, Issue 5, 2005, Pages 385-391

  Luger, Thomas A ^a   Bieber, Thomas ^b   Meurer, Michael ^c   Mrowietz, Ulrich ^d   Schwarz, Thomas ^d   Simon, Jan ^e   Werfel, Thomas ^f   Zuberbier, Torsten ^g  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID; PIMECROLIMUS; STEROID; TACROLIMUS;

ALGORITHM; ATOPIC DERMATITIS; DRUG INDICATION; HUMAN; REVIEW; SYSTEMIC THERAPY; TREATMENT PLANNING; ULTRAVIOLET RADIATION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ALGORITHMS; CALCINEURIN; CHILD; CHILD, PRESCHOOL; CONTROLLED CLINICAL TRIALS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; ECZEMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; OINTMENTS; PRACTICE GUIDELINES; TACROLIMUS; TIME FACTORS;

EID: 19944425176     PISSN: 16100379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Ring J. The therapeutic concept of patient management in atopic eczema. Allergy 1995; 51: 206-215.
2. Abeck D, Strom K. Optimal management of atopic dermatitis. Am J Clin Dermatol 2000; 1: 41-46.
3. Hill C, Rosenberg A. Adverse effects from topical steroids. Cutis 1978; 21: 624-628.
4. Ellis C, and, Luger TA, on behalf of the ICAAD faculty. International consensus conference on atopic dermatitis II (ICCAD II): clinical update and current treatment strategies. Brit J Dermatol 2003; 148: 3-10.
5. Ellis C, Drake LA, Prendergast MM, Abramovits W, Boguniewicz M, Daniel CR, Lebwohl M, Paller AS, Stevens SR, Whitaker-Worth DL, Tong KB. Cost-effectiveness analysis of tacrolimus ointmant versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol 2003; 48: 553-563.
6. www.leitlinien.net: Homepage der Arbeitsgemeinschaft der wissenschaftlichen medizinischen Fachgesellschaften. AWMF-Leitlinien-Register Nr. 013/027 Atopisches Ekzem - gemeinsame Leitlinie der DDG und des BVDD. AWMF-Leitlinien-Register Nr. 013/027 Atopisches Ekzem - gemeinsame Leitlinie der DDG und des BVDD 2004.
7. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141 (2): 264-273.
8. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20(4): 233-241.
9. Billich A, Aschauer H, Stuetz A. Pimecrolimus permeates less through the skin than corticosteroids and tacrolimus. J Invest Derm 2002; 119: 346.
10. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144(3): 507-513.
11. Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, Fölster-Holst R, Potter P, Marshall K, Thurston M, Bush C, Cherill R. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155-162.
12. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, Bush C, Graeber M. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46(4): 495-504.
13. Luger TA, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, Berth Jones J, Bjerke J, Christophers E, Knop J, Knulst AC, Morren M, Morris A, Reitamo S, Roed-Petersen J, Schöpf E, Thestrup-Pedersen K, Van der Valk PGM, Bos J. SDZ ASM981: An emerging new standard for the treatment of atopic dermatitis. Br J Dermatol 2001; (in press).
14. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y, for the Flare Reduction in Ekzema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; (110): 1-8.
15. Kapp A, Papp K, Bingham A, Fölster-Holst R, Ortonne JP, Potter PC, Gulliver W, Paul C, Molloy S, Barbier N, Thurston M, de Prost Y, for the Flare Reduction in Ekzema with Elidel (Infants) Multicenter Investigator Study Group. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277-284.
16. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Bräutigam M, CASM-DE-01 study group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271-277.
17. Luger TA, Lahfa M, Fölster-Holst R, Gulliver W, Allen R, Molloy S, Barbier N, Paul C, Bos JD. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Derm Treat 2004; 15: 169-178.
18. Fujisawa Deutschland GmbH. Protopic 0.03% and 0.1% Fachinformation. Fachinformation 2004.
19. Nakagawa H, Etoh T, Ishibashi Y, Higaki Y, Kawashima M, Torii H, Harada S. Tacrolimus ointment for atopic dermatitis. Lancet 1994; 344: 883.
20. Kapp A, Allen BR, Reitamo S. Atopic dermatitis management with tacrolimus ointment (protopic). J Dermatol Treat 2003; 14: 5-16.
21. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, Cambazard F, Rustin M, Taieb A, Gratton D, Sauder D, Sharpe G, Smith C, Junger M, de Prost Y. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109(3): 539-546.
22. Reitamo S, Harper J, Bos JD, Cambazard F, Bruijnzeel Koomen CA, Valk P, Smith C, Moss C, Dobozy A, Palatsi R, European Tacrolimus Ointment Group. 0.03% Tacrolimus ointment once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150: 554-562.
23. Reitamo S, European Tacrolimus Ointment Study Group. 0.1% Tacrolimus ointment twice daily is an effective treatment for adults with moderate to severe atopic dermatitis. JEADV 2003; 17: 180.
24. Rico MJ, Paller A, Hanifin J, Eichenfield LF. Long-term (more than 3 years) tacrolimus ointment monotherapy effectively controls atopic dermatitis in children and adults. JEADV 2003; 17: 180.
25. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44(1 Suppl): S58-S64.
26. Kawashima M, Nakagawa H, Ohtsuki M, Tamaki K, Ishibashi Y. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet 1996; 348(9036): 1240-1241.
27. Allen BR, Lakhanpaul M, Morris A, Lateo S, Davies T, Scott G, Cardno M, Ebelin ME, Burtin P, Stephenson T. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003; 88: 969-973.
28. Van Leent EJ, Ebelin ME, Burtin P, Spuls PI, Bos JD. Low systemic concentrations of SDZ ASM 981 after topical treatment of extensive atopic dermatitis lesions. JEADV 1998; 11: 133-134.
29. Patel PP, Van der Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol 2003; 139: 1184-1186.
30. Kyllonen H, Remitz A, Mandelin J, Elg P, Reitamo S. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Brit J Dermatol 2004; 150: 1174-1181.
31. Hanifin J, Ho V, Kaufmann R, et al. Pimecrolimus (SDZ ASM 981) cream: good tolerability in paediatric patients. Ann Dermatol Venereol 2002; 129: 411.
32. Robinson N, Singri P, Gordon KB. Safety of the new macrolide immunomodulators. Semin Cutan Med Surg 2001; 20(4): 242-249.
33. Fleischer AB, Jr., Ling M, Eichenfield LF, Satoi Y, Jaracz E, Rico MJ, Maher RM, Tacrolimus Ointment Study Group. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002; 47: 562.
34. Lubbe J. Klinische Erfahrungen mit topischen Calcineurininhibitoren in der Praxis. Hautarzt 2003; 54(5): 432-439.
35. Hoetzenecker W, Meingasser JG, Ecker R, Stingl G, Stuetz A, Elbe-Burger A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122: 673-684.
36. Schuller E, Oppel T, Bornhovd EC, Wetzel S, Wollenberg A. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol 2004; 114: 137-143.
37. Novartis Pharma GmbH. Elidel Fachinformation. Fachinformation 2002.
38. Naylor M, Elmets C, Rico MJ, et al. Treatment with topical tacrolimus is not associated with an increase in melanoma skin cancers. J Am Acad Dermatol 2002.
39. Papp K, Kapp A, Ruer-Mulard M, et al. Pimecrolimus cream 1% provides effective long-term control of atopic dermatitis in infants. J Am Acad Dermatol 2004; 50: 65.
40. Rico MJ, Stiehm ER, Roberts RL, et al. Tacrolimus ointment does not suppress the immune system of children aged 2-12. JEADV 2003; 17: 179.
41. Kaufmann R, Fölster-Holst R, Höger P, Thaci D, Löffler H, Staab D, Bräutigam M. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol 2004; 14: 1183-1188.
42. Diepgen T, Fartasch M, Ring J, Scheewe S, Staab D, Szcepanski R, Werfel T, Wahn U, Gieler U. Neurodermitisschulung. Hautarzt 2003; 54: 946-951.
43. Hanifin J, Gupta A, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Brit J Dermatol 2002; 147: 528-537.
44. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionateadded to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomized, double blind, parallel group study. BMJ 2003; 326: 1367.
45. Spergel JM, Mizoguchi E, Brewer JP, Martin TR, Bhan AK, Geha RS. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 1998; 101: 1614-1622.
46. Kao JS, Fluhr JW, Man MQ, Fowler AJ, Hachem JP, Crumrine D, Ahn SK, Brown BE, Elias PM, Feingold KR. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003; 120(3): 456-464.